Free Trial

Oruka Therapeutics (ORKA) Competitors

Oruka Therapeutics logo
$12.42 +0.62 (+5.21%)
As of 12:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ORKA vs. TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, EWTX, SDGR, and BHVN

Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.

Oruka Therapeutics vs. Its Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 64.55%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 225.21%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Oruka Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Oruka Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Oruka Therapeutics' return on equity of -25.66% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-44.91% -39.72% -25.74%
Oruka Therapeutics N/A -25.66%-23.39%

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 2 articles in the media. Oruka Therapeutics' average media sentiment score of 1.89 beat Tarsus Pharmaceuticals' score of 1.88 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Oruka Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Tarsus Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.

Oruka Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$182.95M9.30-$115.55M-$2.73-14.84
Oruka TherapeuticsN/AN/A-$83.72M-$4.51-2.75

Summary

Oruka Therapeutics beats Tarsus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORKA vs. The Competition

MetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$464.63M$2.42B$5.51B$8.92B
Dividend YieldN/A1.79%5.38%4.12%
P/E Ratio-2.758.9326.2119.84
Price / SalesN/A672.42415.30113.63
Price / CashN/A154.3736.4957.06
Price / Book1.154.548.005.32
Net Income-$83.72M$31.16M$3.15B$248.42M
7 Day Performance6.75%0.15%1.72%2.50%
1 Month Performance5.48%8.72%4.63%5.53%
1 Year PerformanceN/A2.08%35.87%19.65%

Oruka Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORKA
Oruka Therapeutics
3.0293 of 5 stars
$12.42
+5.2%
$40.38
+225.2%
N/A$464.63MN/A-2.75N/ANews Coverage
Positive News
TARS
Tarsus Pharmaceuticals
2.2581 of 5 stars
$40.60
-0.1%
$66.67
+64.2%
+41.6%$1.71B$182.95M-14.8750Positive News
BEAM
Beam Therapeutics
2.0723 of 5 stars
$16.71
-0.3%
$48.75
+191.7%
-23.9%$1.69B$63.52M-3.62510
CNTA
Centessa Pharmaceuticals
3.0937 of 5 stars
$13.00
+4.6%
$27.89
+114.5%
+49.7%$1.66B$6.85M-7.18200
ARQT
Arcutis Biotherapeutics
2.0174 of 5 stars
$14.40
+4.2%
$18.80
+30.6%
+43.8%$1.65B$212.82M-13.85150Positive News
ADPT
Adaptive Biotechnologies
3.4221 of 5 stars
$10.56
+1.7%
$10.57
+0.1%
+210.8%$1.58B$178.96M-11.00790News Coverage
IMCR
Immunocore
2.4455 of 5 stars
$31.12
-0.7%
$58.89
+89.2%
-9.9%$1.57B$310.20M-72.37320
SPRY
ARS Pharmaceuticals
3.0846 of 5 stars
$16.57
+4.9%
$31.00
+87.1%
+84.3%$1.55B$89.15M-103.5690Insider Trade
EWTX
Edgewise Therapeutics
2.6282 of 5 stars
$14.18
-0.8%
$39.78
+180.5%
-33.8%$1.50BN/A-9.1560News Coverage
Analyst Forecast
Analyst Revision
Gap Down
SDGR
Schrodinger
2.6541 of 5 stars
$20.35
-0.5%
$32.80
+61.2%
+9.9%$1.50B$207.54M-7.74790
BHVN
Biohaven
2.7735 of 5 stars
$14.44
-0.2%
$58.46
+305.0%
-60.5%$1.48BN/A-1.54239

Related Companies and Tools


This page (NASDAQ:ORKA) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners